PAVmed (PAVM) Fundamental Analysis: Revenue, Earnings & Valuation

0.36 / 10

Underperform

Fundamental rating is Underperform; health is challenging. ROA (0.84) and asset‑based profit margin rank top quartile, yet Cash‑MV (-0.09) and net cash‑flow to revenue (-19,236%) are deeply negative. Asset‑MV and Revenue‑MV also lag peers, suggesting valuation pressure.

Analysis Checks(6/10)

Revenue-MV

Value-6.09

Score2/3

Weight-23.14%

1M Return1.21%

ROA (%)

Value0.84

Score3/3

Weight-40.09%

1M Return1.81%

Net cash flow from operating activities / Operating revenue (%)

Value-19236.84

Score0/3

Weight80.72%

1M Return-6.63%

Profit-MV

Value0.07

Score1/3

Weight90.36%

1M Return-6.02%

Annualized net profit margin on total assets (%)

Value1.12

Score3/3

Weight-40.09%

1M Return1.81%

EBIT / Total operating revenue (%)

Value1473.68

Score3/3

Weight-34.30%

1M Return1.53%

Asset-MV

Value-0.49

Score2/3

Weight-11.78%

1M Return0.57%

Net profit / Total operating revenue (%)

Value1515.79

Score2/3

Weight-27.28%

1M Return1.26%

Cash-MV

Value-0.09

Score1/3

Weight65.28%

1M Return-4.16%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight40.32%

1M Return-2.39%

Is PAVM fundamentally strong?

PAVM scores 0.36/10 on fundamentals and holds a Premium valuation at present. Backed by its -49.44% ROE, -3477.46% net margin, -3.44 P/E ratio, 0.50 P/B ratio, and -105.68% earnings growth, these metrics solidify its Underperform investment rating.